Barclays sees yesterday’s FDA panel vote on Onpattro as a “clear win” for Alnylam Pharmaceuticals. The firm sees a high probability of approval in cardiomyopathy of transthyretin-mediated amyloidosis. However, Barclays expects limited revenue uptake in ATTR-CM, and emphasizes that major upside potential would likely be from the HELIOS-B trial, for which it sees a good chance of a positive outcome. The firm keeps an Overweight rating on the shares with a $236 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALNY:
- Alnylam (NASDAQ:ALNY) Stock Down Despite a Positive Development
- Alnylam announces positive outcome of FDA AdCom meeting on Patisiran
- Alnylam wins FDA panel backing for Onpattro, Bloomberg reports
- Alnylam reports FDA committee meeting to review sNDA for patisiran
- William Blair still sees approval for Alnylam after briefing docs